Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/11/fabrinet-stock-jumps-as-q2-guidance-crushes-wall-street.jpg

Fabrinet Stock Jumps As Q2 Guidance Crushes Wall Street

TIM BOHEN•UPDATED NOV. 3, 2026, 3:48 PM ET
Reviewed by Ben Sturgilland Fact-checked by Ellis Hobbs

Fabrinet stocks have been trading up by 15.25 percent after strong earnings and upbeat guidance boosted investor optimism.

Key Takeaways For FN Traders

  • Record Q1 FY27 numbers from Fabrinet showed revenue up 51% year-over-year and non-GAAP EPS up about 49%, both running ahead of earlier guidance.
  • Q1 revenue of $1.474B versus $1.4B consensus and adjusted EPS of $4.34 versus $4.19 confirmed stronger-than-expected performance across multiple FN programs.
  • For Q2, management guided EPS to $4.77–$4.92 and revenue to $1.6B–$1.65B, well above Street estimates and signaling strong demand visibility.
  • The board lifted Fabrinet’s share repurchase authorization by $103M to $637.3M, pointing to confidence in FN’s cash generation and valuation.
  • Susquehanna, JPMorgan, and B. Riley trimmed FN price targets but still flagged durable optical and AI demand, keeping Positive or Neutral stances.

Candlestick Chart

Get Free Alerts

Live Update At 15:47:02 EST: On Tuesday, November 03, 2026 Fabrinet stock [NYSE: FN] is trending up by 15.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

FN has been trading like a momentum name, and the numbers back it up. Fabrinet’s latest quarter delivered Q1 revenue of $1.474B, easily ahead of the $1.4B consensus. Adjusted EPS landed at $4.34, topping the $4.19 expectation and confirming strong profitability. Year-over-year, Fabrinet reported revenue growth of 51% and roughly 49% growth in non-GAAP EPS, which is serious acceleration for an established manufacturing partner.

On the chart, FN has cooled off from the $500 area seen in early October 2026 but is stabilizing. The stock slid from an October peak near the high-$400s down toward the low-$300s, then snapped back. After the latest report, FN closed around $362.68, reclaiming key territory and signaling dip buyers are active.

More Breaking News

Intraday action shows tight trading between roughly $360 and $370, with higher lows building through the session. For short-term traders, that intraday staircase pattern often signals accumulation, not panic. Under the hood, Fabrinet’s margins around 12% at the EBIT line and returns on equity above 20% show it is not just growing but doing it efficiently, which many growth stories lack.

Why Traders Are Watching FN Momentum

FN is on every momentum trader’s screen right now because the story checks multiple boxes at once: earnings beat, raised guidance, and a larger buyback. Fabrinet didn’t just edge past estimates; it smashed them and then reset the bar higher. Q2 guidance for EPS at $4.77–$4.92 versus $4.43 consensus and revenue at $1.6B–$1.65B versus $1.48B tells traders management sees strong order visibility across optical and AI-linked programs.

That kind of “beat and raise” from Fabrinet often acts as fuel for multi-day breakouts. The news already triggered a sharp after-hours spike as algos and fast money reacted to the numbers. Many short-term traders look precisely for this setup: strong fundamentals, clear catalysts, and heavy volume into the close.

At the same time, FN isn’t a cheap story. A price-to-earnings ratio around 37 and price-to-sales near 3.75 show traders are paying up for Fabrinet’s growth. Analyst reactions underscore this tension. Susquehanna cut its FN target from $850 to $600 but kept a Positive rating, still leaning on AI demand in a broader semi upcycle. JPMorgan took its target down from $695 to $465 with a Neutral stance, yet highlighted “strong and durable” optical demand into 2027.

B. Riley went even lower at $385, citing worries about tighter credit for large cloud spenders, while admitting near-term demand for Fabrinet and other optical names remains strong. The broader Street still sits around a mean target near $720.70 with an Overweight bias. That spread tells traders one thing: FN’s valuation is controversial, and controversy breeds volatility, which is exactly what active traders hunt.

Conclusion

For traders studying FN, this is a textbook momentum name backed by real numbers, not just hype. Fabrinet just printed record Q1 FY27 results, ramped revenue by more than 50% year-over-year, and posted nearly 49% growth in non-GAAP EPS. Management then doubled down with above-consensus Q2 guidance and a larger $637.3M repurchase plan. That combination often provides both upside momentum and some downside support as buybacks absorb supply.

But the story is not one-way. FN has already seen a big run, and several firms have trimmed price targets, framing the debate around how much future growth is already priced in. For day traders and swing traders, that mix of strong fundamentals, stretched valuation, and split analyst views creates sharp moves both directions.

The job now is to treat Fabrinet like any other hot runner: map your key levels from the recent $300s base up through the mid-$300s and $400 resistance zones, react to volume, and stay unemotional. As Tim Sykes likes to remind his students, “The market doesn’t owe you anything — your edge comes from discipline, not predictions.” In the same spirit of disciplined trading, As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. FN gives plenty of opportunity, but traders still need a plan, tight risk, and the willingness to walk away when the chart turns. This article is for educational and research purposes only and is not trading advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders